Aridis Pharmaceuticals’ $26 Million Initial Public Offering

Sheppard Mullin represented Aridis Pharmaceuticals on the deal

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections, priced its initial public offering of 2,000,000 shares of its common stock at a public offering price of $13.00 per share for total gross proceeds of $26.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Aridis. In addition, Aridis has granted the underwriters a 30-day option to purchase up to 300,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares are being offered by Aridis. The shares are expected to begin trading on the Nasdaq Capital Market on August 14, 2018 under the symbol “ARDS.”

Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering. Maxim Group LLC is acting as lead manager and Laidlaw & Company (UK) Ltd., Northland Securities, Inc. and Seaport Global Securities LLC are acting as co-managers for the offering.

The Sheppard Mullin team included partners Jeff Fessler (Picture), Lorna Tanner and Peter Reichertz, and associates Justin Anslow, Nazia Khan, Joy Nemirow and Alex Nie.

Involved fees earner: Jeffrey Fessler – Sheppard Mullin; Justin Anslow – Sheppard Mullin; Nazia Khan – Sheppard Mullin; Joy Nemirow – Sheppard Mullin; Alex Nie – Sheppard Mullin; Peter Reichertz – Sheppard Mullin; Lorna Tanner – Sheppard Mullin;

Law Firms: Sheppard Mullin;

Clients: Aridis Pharmaceuticals;


Author: Ambrogio Visconti